Ligands for aggregated tau molecules: WO2010034982

Steven John Kemp; John Mervyn David Storey; Janet Elizabeth Rickard; Charles Robert Harrington; David Horsley; Claude Michel Wischik; Scott Clunas; Tobias Heinrich

Ligands for aggregated tau molecules: WO2010034982

Steven John Kemp (Inventor), John Mervyn David Storey (Inventor), Janet Elizabeth Rickard (Inventor), Charles Robert Harrington (Inventor), David Horsley (Inventor), Claude Michel Wischik (Inventor), Scott Clunas (Inventor), Tobias Heinrich (Inventor)

Research output: Patent

15 Downloads (Pure)

Abstract

Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example:<structures> and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

Original language	English
Patent number	WO2010/034982
Publication status	Published - 1 Apr 2010

Access to Document

WO2010034982

Development of treatments & diagnostics for Alzheimer’s disease
John Storey (Coordinator)
Impact: Other Impacts
Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease
Claude Wischik (Participant), Charles Harrington (Participant), John Storey (Participant), Janet Rickard (Participant), David Horsley (Participant), Thomas Baddeley (Participant), Steven Kemp (Participant), James Sinclair (Participant), Claudia Zabke (Participant), F. Theuring (Participant), F Stamer (Participant) & C Marshall (Participant)
Impact: Quality of life Impacts, Economic Impacts

Cite this

@misc{a7e3540288754dc781d369c94d424344,

title = "Ligands for aggregated tau molecules: WO2010034982",

abstract = "Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.",

author = "Kemp, {Steven John} and Storey, {John Mervyn David} and Rickard, {Janet Elizabeth} and Harrington, {Charles Robert} and David Horsley and Wischik, {Claude Michel} and Scott Clunas and Tobias Heinrich",

year = "2010",

month = apr,

day = "1",

language = "English",

type = "Patent",

note = "WO2010/034982",

}

TY - PAT

T1 - Ligands for aggregated tau molecules

T2 - WO2010034982

AU - Kemp, Steven John

AU - Storey, John Mervyn David

AU - Rickard, Janet Elizabeth

AU - Harrington, Charles Robert

AU - Horsley, David

AU - Wischik, Claude Michel

AU - Clunas, Scott

AU - Heinrich, Tobias

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

AB - Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.

M3 - Patent

M1 - WO2010/034982

ER -

Ligands for aggregated tau molecules: WO2010034982

Abstract

Access to Document

Fingerprint

Impacts

Development of treatments & diagnostics for Alzheimer’s disease

Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease

Cite this